Jan 28 (Reuters) - Regenxbio said on Wednesday the U.S. Food and Drug Administration has placed a clinical hold on two of its ...
A plan to slash Food and Drug Administration drug review times is raising alarms at the public health agency that's been ...
The initiative could tackle the first-mover disadvantage some CDMOs believe deters early customers, but leaders at companies ...
Questions remain among top Food and Drug Administration officials over who has the appropriate legal authority to sign off on ...
More than half a dozen major drugmakers are participating in the Trump administration's speedier review program for new ...
After a patient safety signal and then death, the FDA in October 2025 placed holds on two of the company’s CRISPR programs ...
On September 29, 2025, the U.S. Food and Drug Administration (FDA) announced the expansion of its Early Alert program to include all medical devices. This expansion builds on a pilot program that ...
On October 3, 2025, the U.S. Food and Drug Administration (FDA) unveiled a pilot prioritization program that provides for accelerated review of abbreviated new drug applications (ANDAs) for generic ...
13don MSN
Exclusive-US FDA delays two drug reviews in new voucher program after safety, efficacy concerns
By Patrick Wingrove Jan 15 (Reuters) - The U.S. Food and Drug Administration has delayed reviews of two drugs chosen for the ...
The FDA is moving forward surprisingly quickly with its plan to create a pre-certification program for digital health app developers, originally announced in a blog post by new FDA Commissioner Dr.
FDA delays drug reviews for two priority voucher drugs amid safety and efficacy concerns, extending timelines for Sanofi and Disc Medicine products.
SAN FRANCISCO, CA / ACCESS Newswire / September 30, 2025 / Jaguar Health (NASDAQ:JAGX) today announced that Jaguar family company Napo Pharmaceuticals (Napo) is providing the company’s novel ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results